deliv anoth sold quarter ep ahead
ms growth us masks/oth continu trend
think sustain across
ow long durat growth support larg instal base growth ii
sale iv on-going oper leverag see next major catalyst defin
street assess long-term growth us due announc sleep
lead item price us summer inc correct
point report global mask sale grew constant fx
outpac global devic sale contribut higher gm vs pcp ii
row devic constant fx line expect step start
iii lfl ep vs ms driven aforement
mask strength sg sale low end guidanc
differ see upsid risk still us mask sale less
gm pressur past year us reimburs stabl
least jan robust resuppli trend continu ii upsid
penetr copd market yet unfurl via portabl oxygen
concentr propel health iii recoveri row devic
softwar invest underpin long-term growth expertis patient
connect within osa ecosystem born fruit patient complianc
improv resuppli move higher demonstr us mask/oth
revenu growth three consecut quarter high-teen growth
upsid limit though maintain ow healthcar stock ralli
averag coverag offer downsid think better
posit particularli large-cap player good bull case
potenti cochlear large-cap peer rate ew comparison
downsid base case expect double-digit ep growth
ii robust row resuppli growth iii strong cash gener underpin
strong de-lever balanc sheet iv better growth poc
copd franchis vs connect care invest repres long-term upsid
street expect risk wrong volum trend resuppli
avail headroom allow smaller think
downsid risk estim
appreci support
institut investor all-asia
research survey vote open earli
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject finra restrict commun subject
compani public appear trade secur held
result review
global resuppli cc us mask sale vs mse row resuppli
sale cc vs mse strong us mask sale key driver behind stronger-than-
row devic growth cc row devic sale mse cite
continu headwind franc expect return normal growth rather
end
oper leverag achiev gp margin improv mse
 expens mse net incom oper
ahead mse balanc expect sale
 sale
non-gaap net incom non-gaap net incom ahead
mse partli due effect tax rate vs mse impact
tax benefit detail call exclud effect tax rate
ep ahead mse expect effect tax rate go forward
compani data morgan stanley research estim mse account verili cost pre-tax profit number adjust show like-for-lik basi
chang forecast
us mask revenu grew vs expect
saa revenu came expect led low singl digit
downgrad revenu
advis call propel health busi report within mask
revenu previous includ propel contribut saa
small chang ep driven chang forecast
exhibit chang estim follow
compani data morgan stanley research account verili cost pre-tax profit number adjust show like-for-lik basi
wide dispers outcom exist
price target base blend bull base bear case scenario valu weight
respect given asx scarciti defens earn growth view
continu trade toward bull case valuat henc scenario weight
base case valu use dcf methodolog wacc lt growth
rate ow see long durat
growth support larg instal
drive higher resuppli sale iii on-going
view descript risk reward theme
us eu devic revenu growth
volum growth pa iv asp
pressur gm next year
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
reduct us mask price ii poc
remain market share iii
devic price iv resuppli volum
growth line devic growth
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
research highest favor quintil
higher market share cpap
faster-than-expect benet recent
round competit bid
advers impact us competit bid
loss cpap market share
eur usd continu deterior
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
wide dispers outcom exist
price target cdi deriv price target use ratio cdi
investor awar calcul take account issu risk
associ invest adr includ limit liquid vote right
dividend volatil currenc exchang rate uctuat
rate ow see long durat
growth support larg instal
drive higher resuppli sale iii on-going
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
us devic growth higher current
forecast addit small move mask
turn see upsid poc reach
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
bear case assum reduct us
mask price reduct us unit growth
remain intern level pa
poc remain market share
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
higher market share cpap
faster-than-expect benet recent
round competit bid
advers impact us competit bid
loss cpap market share
eur usd continu deterior affect
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
note provid research coverag list cdi associ underli ordinari share compani courtesi may includ cdi price target cdi share price aud
dollar research report unless otherwis state cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar
calcul take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
exhibit statist resm cdi
price target convert cdi
cdi disclaim end report morgan stanley research
valuat methodolog risk
price target set use blend methodolog scenario weight assign
bull base bear case valuat
given asx scarciti defens earn growth view continu
trade toward bull case valuat
assign weight bull case base case bear case
base case valu use dcf methodolog wacc lt growth
risk upsid
post-nucleu sale backwards-compat processor weaken
risk downsid
reimburs restrict us develop eu strengthen
disappoint uptak new product
